載入中
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
前收盤價
US$21.12
+US$0.99 · +4.92%
盤中時間採用ET。市場資料可能有所延遲。
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
日內區間
目前US$21.12
52週區間
目前US$21.12
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$37.33
上漲空間 76.75%價格歷史記錄不可用
最高：US$40.00平均的：US$37.33最低：US$33.00AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
